Kaleido Biosciences, Inc. is a company.
Key people at Kaleido Biosciences, Inc..
Kaleido Biosciences, Inc. was founded by Brian Baynes (Member of the Board of Directors; Co-Founder).
Kaleido Biosciences, Inc. was founded by Brian Baynes (Member of the Board of Directors; Co-Founder).
Key people at Kaleido Biosciences, Inc..
Kaleido Biosciences, Inc. is a clinical-stage biotechnology company developing Microbiome Metabolic Therapies (MMT™), novel small-molecule chemistries that modulate the metabolic output of the human microbiome to treat diseases.[1][2][3][4] It targets conditions like urea cycle disorders, hepatic encephalopathy, ulcerative colitis, immuno-oncology, infectious diseases, and metabolic disorders by shaping the microbiome as a single organ rather than adding or removing specific microbes.[1][2][3] The company serves patients with unmet needs in rare genetic diseases, oncology, inflammation, and metabolic health, solving problems tied to dysregulated microbiome function through its high-throughput screening platform and rapid clinical advancement.[1][2][4] Founded in 2015 and headquartered in Bedford, Massachusetts, Kaleido raised significant funding—including a $101M Series C—and built a broad pipeline with over 3,000 days of human data by 2017, though several candidates like KB-174 and KB-109 were later discontinued.[1][2][5]
Kaleido Biosciences was founded in 2015 by Flagship Pioneering, a life sciences innovation firm, with key figures including Geoffrey von Maltzahn and Noubar Afeyan (Flagship's founder).[1][3] It operated in stealth mode until September 2017, when Flagship unveiled it with $65M in initial capitalization, drawing on Flagship's decade-long microbiome investments that also birthed companies like Seres Therapeutics and Evelo Biosciences.[1] The idea emerged from Flagship's expertise in microbiome science, focusing on chemistry-driven modulation rather than microbial transplantation to unlock therapeutic potential across diseases.[1][2] Early traction included rapid generation of human data from novel chemistries, over 10 pre-IND studies by 2020, and appointment of Mike Bonney—former CEO of Cubist Pharmaceuticals (acquired by Merck for $9.5B)—as CEO in 2017.[1][2][3]
Kaleido stands out in the microbiome field through these key strengths:
Kaleido rides the microbiome therapeutics wave, a trend recognizing the gut microbiome as a "virtual organ" influencing immunity, metabolism, and disease—linked to autoimmune, metabolic syndrome, oncology, and infections.[1][2][3][4] Timing aligns with post-2010s advances in sequencing (e.g., CoreBiome partnership) and high-throughput tools, enabling precise metabolic modulation amid failures of live-biotherapeutic products.[2] Market forces favor it: rising unmet needs in rare diseases and inflammation, regulatory flexibility for food-grade studies, and investor interest (e.g., $101M Series C).[2] Kaleido influences the ecosystem by pioneering chemistry over biologics, inspiring hybrid drug-nutrition models and collaborations like Janssen's, potentially expanding microbiome tech beyond pharma into consumer health.[1][4]
Kaleido's differentiated MMT platform positions it to revive microbiome innovation despite discontinuations like KB-174 (hyperammonemia) and KB-109 (COPD), with pending assets like KB-295 (ulcerative colitis) and preclinical advances in liver disease, atopic dermatitis, and C. difficile.[3][5] Next steps likely include doubling pipelines (as planned for 2021), leveraging Janssen for pediatric applications, and pushing IND-stage therapeutics amid trends like AI-driven screening and personalized microbiomes.[3][4] Its influence may evolve toward metabolic/immune leaders if Phase 2 data in hepatic encephalopathy or IBD succeeds, capitalizing on post-pandemic gut health focus—but success hinges on clinical proof beyond early human data. This chemistry pioneer could redefine microbiome health from stealth origins to mainstream impact.[1][2][5]
